Comparison of different therapeutic strategies in hypertension: A low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach

Journal of Hypertension

Volumn 22, Issue 12, 2004, Pages 2379-2386

  Mourad, Jean Jacques ^a   Waeber, Bernard ^b   Zannad, Faïez ^c   Laville, Maurice ^d   Duru, Gérard ^e   Andréjak, Michel ^f  

^a AVICENNE HOSPITAL   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY HOSPITAL OF NANCY   (France)

^d University Hospital   (France)

^e CNRS   (France)

^f Divisions of Clinical   (France)

Author keywords

Amlodipine; Atenolol; Fixed dose combination; Hydrochlorothiazide; Indapamide; Losartan; Perindopril; Sequential monotherapy; Stepped care treatment; Valsartan

Indexed keywords

AMLODIPINE; ATENOLOL; HYDROCHLOROTHIAZIDE; INDAPAMIDE; LOSARTAN; PERINDOPRIL; VALSARTAN;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASTHENIA; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; ENCAPSULATION; ESSENTIAL HYPERTENSION; FACE EDEMA; FEMALE; HEADACHE; HUMAN; IMPOTENCE; INTERMETHOD COMPARISON; LOW DRUG DOSE; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MUSCLE CRAMP; ORTHOSTATIC HYPOTENSION; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SINGLE BLIND PROCEDURE; TABLET; TREATMENT PLANNING;

EID: 4644239328     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-200412000-00021     Document Type: Article

References (23)

1. European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension, 2003. J Hypertens 2003; 21:1011-1053.
2. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42:1206-1252.
3. World Health Organization. (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21:1983-1992.
4. Lemogoum D, Seedat YK, Mabadeje AF, Mendis S, Bovet P, Onwubere B, et al. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens 2003; 21:1993-2000.
5. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999; 353:2008-2013.
6. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345:851-860.
7. Brenner BM, Cooper ME, Zeeuw D de, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345:861-869.
8. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345:870-878.
9. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U de, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359:995-1003.
10. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker versus diuretic. JAMA 2002; 288:2981-2997.
11. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA 2003; 290:2805-2816.
12. Brunner HR, Menard J, Waeber B, Burnier M, Biollaz J, Nussberger J, Bellet M. Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990; 8:3-11.
13. Epstein M, Bakris G. Newer approaches to antihypertensive therapy. Use of fixed-dose combination therapy. Arch Intern Med 1996; 156:1969-1978.
14. Neutel JM, Smith DH, Weber MA. Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am J Hypertens 2001; 14:286-292.
15. Waeber B. Very-low-dose combination: a first-line choice for the treatment of hypertension? J Hypertens 2003; 21(Suppl 3):S3-S10.
16. Laurent S. Clinical benefit of very-low-dose perindopril-indapamide combination in hypertension. J Hypertens 2001; 19(Suppl 4):9-14.
17. Chalmers J, Castaigne A, Morgan T, Chastang C. Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/diuretic combination as first-line therapy in elderly hypertensive patients. J Hypertens 2000; 18:327-337.
18. Franklin SS, Larson MG, Khan SA, Wong ND, Leip EP, Kannel WB, Levy D. Does the relation of blood pressure to coronary heart disease risk change with aging? Framingham Heart Study Circ 2001; 103:1245-1249.
19. Vlachopoulos C, O'Rourke M. Diastolic pressure, systolic pressure, or pulse pressure? Current Hypertens Rep 2000; 2:271-279.
20. Mourad JJ, Blacher J, Blin P, Warzocha U. Conventional antihypertensive drug therapy does not prevent the increase of pulse pressure with age. Hypertension 2001; 38:958-961.
21. Swales JD. Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am Heart J 1999; 138:231-237.
22. Hyman DJ, Pavlik VN. Self-reported hypertension treatment practices among primary care physicians: blood pressure thresholds, drug choices, and the role of guidelines and evidence-based medicine. Arch Intern Med 2000; 160:2281-2286.
23. Oliveria SA, Lapuerta P, McCarthy BD, L'Italien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162:413-420.